Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of dipyrone (metamizole), chlorpheniramine maleate, and phenylephrine hydrochloride is a multi-ingredient pharmaceutical formulation used for the symptomatic relief of the common cold, influenza, and related upper respiratory tract infections. Primarily marketed in regions such as Brazil, this combination provides a triple therapeutic approach: **dipyrone** acts as a non-opioid analgesic and antipyretic by inhibiting prostaglandin synthesis; **chlorpheniramine maleate** is a first-generation antihistamine that reduces symptoms such as sneezing, rhinorrhea, and watery eyes by antagonizing histamine H1 receptors; and **phenylephrine hydrochloride** is a sympathomimetic decongestant that acts as an alpha-1 adrenergic receptor agonist to constrict blood vessels in the nasal passages, thereby reducing congestion. This specific triple combination is most commonly found in oral solution or liquid drops formulations, whereas capsule versions of similar brands often substitute dipyrone with paracetamol or acetylsalicylic acid.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dipyrone + chlorpheniramine maleate + phenylephrine hydrochloride.